Product Description:

• TYSABRI® (natalizumab) is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TYSABRI increases the risk of PML. When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk.

How to use:

• 300-mg infusion every 4 weeks

Caution & Warnings:

• TYSABRI is contraindicated in patients who have or have had PML
• TYSABRI is contraindicated in patients who have had a hypersensitivity reaction to TYSABRI

Side Effects:

• Headache
• Fatigue
• Infusion-Related Reactions
• Hypersensitivity Reactions
• Increased Risk Of Progressive Multifocal Leukoencephalopathy (Pml)

Ingredients:

• Natalizumab 300Mg/15Ml.